Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

The National Institute for Health and Care Excellence (NICE) invited the company that manufactures ramucirumab (Cyramza(®), Eli Lilly and Company) to submit evidence of the clinical and cost effectiveness of the drug administered alone (monotherapy) or with paclitaxel (combination therapy) for treat...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Pharmacoeconomics
Main Authors: Büyükkaramikli, Nasuh C., Blommestein, Hedwig M., Riemsma, Rob, Armstrong, Nigel, Clay, Fiona. J., Ross, Janine, Worthy, Gill, Severens, Johan, Kleijnen, Jos, Al, Maiwenn J.
Formato: Artigo
Idioma:Inglês
Publicado: Springer International Publishing 2017
Assuntos:
Review Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5684255/
https://ncbi.nlm.nih.gov/pubmed/28656543
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40273-017-0528-y
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares